N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸
![N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 结构式](https://img.chemicalbook.com/CAS/GIF/199850-67-4.gif)
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 性质
| 熔点 | 192-193℃ |
|---|---|
| 密度 | 1.457 |
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | DMF：50mg/mL； DMSO：50mg/mL； DMSO:PBS (pH 7.2) (1:1)：0.5 mg/ml；乙醇：10mg/mL |
| 形态 | 结晶固体 |
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 用途与合成方法
|
MMP-2 4 nM (IC 50 ) |
MMP-3 7 nM (IC 50 ) |
MMP-13 8 nM (IC 50 ) |
MMP-1 6.0 μM (IC 50 ) |
MMP-7 7.2 μM (IC 50 ) |
MMP-9 7.9 μM (IC 50 ) |
PD-166793 (0.1 μM) leads to a 20% inhibition of AMP deaminase (AMPD) activity in rat heart homogenates.
PD-166793 (100 μM; 36 h) significantly reduces MMP‐9 activity in normal human cardiac fibroblasts.
PD-166793 (1 mg/kg/d; daily gavage for 10 weeks) largely prevents the adverse remodeling characteristically seen in the aortocaval (AV) fistula model.
PD-166793 (5 mg/kg; oral gavage) exhibits superior pharmacokinetics (t
1/2
=43.6 h, C
max
=42.4 µg/mL, AUC
0-∞
=2822 µg•h/mL) in rats.
| Animal Model: | Male Sprague-Dawley rats (6 weeks) were induced chronic biventricular volume overload |
| Dosage: | 1 mg/kg |
| Administration: | Daily gavage beginning 2 weeks before surgery and continued until 8 weeks after surgery |
| Result: | Prevented ventricular dilatation and attenuated the hypertrophy typically induced by chronic volume overload. |
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-107428 | N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 | 199850-67-4 | 5mg | 1100 |
| 2024-01-25 | HY-107428 | 10 mM * 1 mLin DMSO | 1210 |
